Day case Rezum™ water vapour therapy for urinary retention secondary to benign prostatic hyperplasia

Abstract

Objectives:

Rezum (Boston Scientific) water vapour therapy is an effective day case minimally invasive surgical treatment (MIST) for men with troublesome lower urinary tract symptoms (LUTSs) due to benign prostatic obstruction. The potential place for MISTs in the treatment of patients with urinary retention or permanent catheter dependence is currently unclear.

Patients and Methods:

A total of 48 patients presenting with retention of urine (out of a total of 524 patients) over a 4-year period from 2017 underwent Rezum treatment. All patients were followed up at 3, 6 and 12 months after the procedure. At each visit, flow rate, post void residual urine, and patient reported outcome measures (PROMs) including International Prostate Symptom Score (IPSS) were recorded.

Results:

A total of 34 patients had an indwelling catheter prior to treatment and 14 were self-catheterising. The mean age was 67 years (standard deviation (SD) = 3) with a mean prostate volume of 56 mL (SD = 6). The average number of injections per case was 8 (SD1), which included median lobe (ML) treatment in one man. 75% of the patients passed their post treatment trial without catheter (TWOC). IPSS improved to 6 (p = 0.001) in 12 months.

Conclusion:

The results from this cohort of patients are encouraging. Further evaluation with longer follow-up is required. The addition of MISTs to the portfolio of options for men with retention of urine may offer a streamlined and efficient alternative to the conventional treatments, and help therefore to reduce the national waiting list, and allow men a more rapid solution avoiding prolonged catheterisation.

Level of evidence:

Not applicable.

Keywords

Rezum BOO surgery MIST BPH urine retention

Get full access to this article

View all access options for this article.

References

Joshi

Sali

Paramore

, et al. Current process and outcomes of the surgical management of LUTS due to benign prostatic enlargement: How consistent are we? – Results from the multi-institutional audit of surgical management of BPE (AuSuM BPE) in the United Kingdom. Scott Med J 2021; 66(2): 58–65.

Fisher

Subramonian

Omar

MI.

The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev 2014; 6: CD006744.

Excellence NIfHaC. Lower urinary tract symptoms in men: Management. London: National Institute for Health and Care Excellence, 2015.

Chacko

Donovan

Abrams

, et al. Transurethral prostatic resection or laser therapy for men with acute urinary retention: The ClasP randomized trial. J Urol 2001; 166(1): 166–171.

Sajan

Mehta

Desai

, et al. Minimally invasive treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. J Vasc Interv Radiol 2022; 33: 359–367.e8.

McVary

Gange

Gittelman

, et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195(5): 1529–1538.

[MTG49] Mtg. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia, NICE2020, https://www.nice.org.uk/guidance/mtg49

Haroon

Khan

McNicholas

, et al. Introduction of Rezum system technology to Ireland for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A pilot study on early outcomes and procedure cost analysis. Irish J Med Sci 2021; 191: 421–426.

Dixon

Rijo Cedano

Mynderse

, et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm® system: Evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 2015; 7: 13–18.

10.

Johnston

Noureldin

Abdelmotagly

, et al. Rezum water vapour therapy: Promising early outcomes from the first UK series. BJU Int 2020; 126(5): 557–558.

11.

Mollengarden

Goldberg

Wong

, et al. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: A single office experience. Prostate Cancer Prostatic Dis 2018; 21(3): 379–385.

12.

Gupta

Holland

Delfino

, et al. MP27-20 convective radiofrequency water vapor energy prostate ablation (Rezum®) effectively treats urinary retention. J Urology 2017; 197(4S): e337.

13.

Wong

Mahmalji

The role of Rezūm ™ team ablation of the prostate in the treatment of patients with acute urinary retention secondary to benign prostatic hyperplasia. Aging Male 2020; 23(5): 1620–1626.

14.

Losco

Mark

Jowitt

Transurethral prostate resection for urinary retention: Does age affect outcome. ANZ J Surg 2013; 83(4): 243–245.

15.

McVary

Rogers

Roehrborn

CG.

Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171–179.

16.

Kayes

Page

Barber

, et al. Prostatic urethral lift treatment in subjects with acute urinary retention (PULSAR), https://www.ics.org/2019/abstract/679

17.

Abt

Hechelhammer

Müllhaupt

, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomised, open label, non-inferiority trial. BMJ 2018; 361: k2338.

18.

Whiting

Noureldin

Abdelmotagly

, et al. Real-world early outcomes and retreatment rates following water vapour ablative therapy for symptomatic benign prostatic hyperplasia. Eur Urol Open Sci 2022; 39: 72–78.